Cartesian Therapeutics (RNAC) Stock Forecast: StockMap's 2-Week Call
RNAC stock forecast: StockMap's model leans Underperform on Cartesian Therapeutics for the two weeks after the Nov 19 close, toward RNAC trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 5 of 6 two-week windows on RNAC since Aug 21; by chance, a call on the same dates was right 60% of the time.
Cartesian Therapeutics last closed at $5.89, -6.51% on the session.
Against the IVW growth benchmark the position is -4.18% over the forecast window.
Cartesian Therapeutics' market cap is $179.66M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -42 (too close to call).
Where RNAC sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 0 bullish and 15 bearish.
Agreement across those insights is 100%.
48 daily calls for RNAC so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Cartesian Therapeutics in the 97th percentile on return on equity, where 100 is best.
Cartesian Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Cartesian Therapeutics as the 243rd largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Cartesian Therapeutics ranks 318th of 394 in the group, against a group median of -0.27.